PreSENTIA Genetic Cancer Screening Tests

PreSENTIA Genetic Cancer Screening Tests : Advanced Detection for Proactive Health

The PreSENTIA Genetic Cancer test is an advanced screening method designed to detect genetic mutations associated with various types of cancer. This test examines an individual's DNA to identify specific genetic changes that might increase the risk of developing certain cancers. By analyzing genetic markers, it aims to provide personalized insights into an individual's predisposition to specific types of cancer, enabling proactive measures for early detection, prevention, and personalized treatment plans.

How Many Attempts to Collect the Blood Sample?

Please take note of the following in our Phlebotomy policy, Each staff member is permitted only two attempts to collect a blood sample from a patient.
However, if a patient's veins are difficult to access, another phlebotomist may take over the collection, or the patient will be rebooked to be attended by Our Senior Registered Manager, with the patient's consent.

To secure your appointment at Miracle Inside Diagnostic Scan Centre, the following payments are required:

Deposit: A non-refundable deposit of £30.
Phlebotomy Charges: An additional fee of £25 is charged for phlebotomy services and DHL courier service to timely deliver the blood to the laboratory.

These payments must be made when booking to confirm your appointment. The remaining balance for your services can be paid through our website after your appointment. This ensures a smooth and efficient process for both our staff and patients. For any questions or assistance regarding payment, don't hesitate to get in touch with our customer service team at 01134608760 This is just a small sample of the many blood tests provided by Miracle Inside. Please contact our expert healthcare professional for advice on the most appropriate tests for your condition during your consultation..

Online Booking System

PreSENTIA Hereditary Cancer Tests - £550

PreSENTIA hereditary cancer test panels by NIPD Genetics can detect numerous inherited genetic changes (mutations) that could cause cancer in the future. NIPD Genetics is a leading innovative biotechnology company active in the field of developing, engineering, and providing in vitro genetic testing solutions. NIPD Genetics laboratories are accredited by CAP and certified by CLIA and ISO standards and provide SAFE, ACCURATE, and RELIABLE in vitro genetic testing services internationally. https://www.nipd.com/products/oncology/presentia/ PreSENTIA offers an extensive portfolio of 19 Hereditary cancer test panels. Each panel focuses on a set of genes that determine someone’s chances of developing specific cancer in the future. The genetic changes in the genes that could cause cancer are inherited from parents to their children and are present from birth. Knowing that a person carries one of these genetic mutations can help them take preventative measures and plan more informed clinical management. As a result, early detection of cancer can be achieved – which increases the chances of successful treatment – or prevention We provide a same-day blood result service for some blood tests (Monday – Friday, excluding Bank Holidays). A £ 25 for Phlebotomy + Courier charge will be applied for all Bloods. Please inform us at the time of booking if you require same-day results. Who is this test for? According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have: Several family members on the same side of the family with cancer

Multiple cancers in the same family member
Family members with early cancer onset
Family members with rare cancer types
Family members with an unusual type of cancer (breast cancer in a male)
Personal or family history of a hereditary cancer syndrome
A family member that has been diagnosed with a germline mutation associated with cancer susceptibility History of previous malignancies

HOW does PreSENTIA HELP you? PreSENTIA panels test for numerous genetic changes that are responsible for causing hereditary cancers. If you want to know more about your cancer risks, or if you have been already diagnosed with cancer and you want to know whether your cancer is hereditary, PreSENTIA can help.

Targeted cancer monitoring – recommended screening tests at key time intervals to detect cancer early, when treatment is more beneficial
Prevention of cancer by prophylactic measures Actionable information for family members who might carry the same gene
Improved classification of the disease for better clinical management
Drug therapy (chemoprevention)

We provide a same-day blood result service for some blood tests (Monday – Friday, excluding Bank Holidays). A £ 25 for Phlebotomy + Courier charge will be applied for all Bloods. Please inform us at the time of booking if you require same-day results. WHY CHOOSE THE PreSENTIA TEST?

Assesses clinically important mutations
Ability to select the best panel for you
Reliable technology
Short turn-around time
Safe and easy to perform

Various PreSENTIA hereditary cancer test panels:

PreSENTIA Hereditary Breast / Gynaecological cancer panel - £ 575

Hereditary Breast/Gynecological cancer panel tests for numerous germline mutations that could cause Breast, Ovarian or Endometrial cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. No of Genes Tested: 26 ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53 Disorders that are related to this Panel: 12

Ataxia-telangiectasia syndrome (ATM)
Constitutional mismatch repair syndrome (EPCAM, MSH2,
MSH6, MLH1, PMS2)
DICER 1 syndrome (DICER1)
Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
Hereditary diffuse gastric syndrome (CDH1)
Li-Fraumeni syndrome (TP53)
Li-Fraumeni syndrome 2 (CHEK2)
Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
MUTYH-associated polyposis syndrome (MUTYH)
Peutz-Jeghers syndrome (STK11)
Polymerase proofreading associated syndrome (POLD1, POLE)
PTEN hamartoma syndrome (PTEN)
The genes that are not linked with hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel: BARD1, BRIP, MRE11, NBN, PALB2, RAD50, RAD51C, RAD51D, SMARCA4

To Book this PreSENTIA, please Click BOOK NOW

PreSENTIA Hereditary Breast / Gynaecological guidelines-based - £575

Hereditary Breast/Gynecological cancer guidelines-based panel tests for numerous germline mutations that could cause Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. No of Genes Tested : 19 ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, STK11 Disorders that are related to this Panel : 9

Ataxia telangiectasia syndrome (ATM)
Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
Hereditary diffuse gastric syndrome (CDH1)
Li-Fraumeni syndrome (TP53)
Li-Fraumeni syndrome 2 (CHEK2)
Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
Peutz-Jeghers syndrome (STK11)
PTEN Hamartoma syndrome (PTEN)

The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk and are also analysed by this panel: BARD1, BRIP, NBN, PALB2, RAD51C, RAD51D To Book this PreSENTIA, Appointment , please CLICK HERE

PreSENTIA Hereditary Breast High-Risk - £550

Hereditary Breast High-Risk cancer panel tests for numerous germline mutations that are associated with a high risk for developing Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. No of Genes Tested : 7 BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53 Disorders associated with this panel : 5

Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
Hereditary diffuse gastric syndrome (CDH1)
Li-Fraumeni syndrome (TP53)
Peutz-Jeughers syndrome (STK11)
PTEN hamartoma syndrome (PTEN)

The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel: PALB2 To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary BRCA1/BRCA2 cancer panel - £ 304

Hereditary BRCA1/BRCA2 cancer panel tests for germline mutations in the BRCA1 and BRCA2 genes that could cause specific cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. No of Genes Tested : 2 BRCA1, BRCA2 Disorders associated with this panel: 1 Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2) To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Colorectal Cancer Panel - £ 575

Hereditary Colorectal Cancer Panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. No of Genes Tested: 17 APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53 Disorders associated with this panel: 12

Familial Adenomatous Polyposis / Attenuated Familial
Adenomatous Polyposis (APC)
Li-Fraumeni syndrome (TP53)
Li-Fraumeni syndrome 2 (CHEK2)
PTEN Hamartoma syndrome (PTEN)
Peutz-Jeghers syndrome (STK11)
Hereditary diffuse gastric syndrome (CDH1)
MUTYH-associated polyposis syndrome (MUTYH)
Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
Polymerase Proofreading Associated Syndrome (POLD1, POLE)
Hereditary mixed polyposis syndrome (GREM1)
Juvenile Polyposis Syndrome (SMAD4, BMPR1A)
Constitutional Mismatch Repair syndrome (MSH2, MSH6, MLH1, PMS2)

To Book this PreSENTIA, please Click BOOK NOW

PreSENTIA Hereditary Colorectal High-Risk cancer panel - £ 550

Hereditary Colorectal High-Risk cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. No of Genes Tested : 10 APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11 Disorders associated with this panel : 6

Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
Juvenile polyposis syndrome (SMAD4, BMPR1A)
Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
MUTYH-associated polyposis syndrome (MUTYH)
Peutz-Jeghers syndrome (STK11)

To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Colorectal Non-Polyposis cancer panel - £ 550

Hereditary Colorectal High-Risk cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. No of Genes Tested : 10 APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11 Disorders associated with this panel : 6

Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
Juvenile polyposis syndrome (SMAD4, BMPR1A)
Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
MUTYH-associated polyposis syndrome (MUTYH) Peutz-Jeghers syndrome (STK11)

To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Colorectal Polyposis syndrome cancer panel - £ 550

Hereditary Colorectal Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. No of Genes Tested : 7 APC, BMPR1A, MUTYH, POLD1, POLE, SMAD4,STK11 Disorders associated with this panel: 5

Familial Adenomatous Polyposis / Attenuated Familial
Adenomatous Polyposis (APC)
Juvenile polyposis syndrome (SMAD4, BMPR1A)
MUTYH-associated polyposis syndrome (MUTYH)
Peutz-Jeghers syndrome (STK11)
Polymerase proofreading-associated syndrome (POLD1, POLE)

To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Myelodysplastic syndrome / Leukaemia cancer panel - £ 625

Hereditary Myelodysplastic syndrome / Leukaemia cancer panel tests for numerous germline mutations that could cause blood cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. Who is this test for? According to genetic testing guidelines, people who might benefit from genetic testing for hereditary myelodysplastic syndromes or leukaemias are those who have:

Family history of a hereditary cancer syndrome associated with leukaemia
Personal history of a hereditary cancer syndrome associated with leukaemia
An identical twin who developed leukaemia in the first year of life
A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

No of Genes Tested: 24 ATM, BRCA1, BRCA2, BRIP1, EPCAM, ERCC4, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51C, SLX4, TP53 Disorders associated with this panel: 6

Ataxia-telangiectasia syndrome (ATM)
Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
Fanconi anaemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
Hereditary breast & ovarian syndrome (BRCA1 & BRCA2)
Li-Fraumeni syndrome (TP53)
Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)

To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Gastric Cancer Panel - £ 575

Hereditary Gastric Cancer Panel tests for numerous inherited germline mutations that could cause gastric (stomach) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. Who is this test for? According to genetic testing guidelines, people who might benefit from genetic testing for hereditary myelodysplastic syndromes or leukaemias are those who have:

Family history of a hereditary cancer syndrome associated with leukaemia
Personal history of a hereditary cancer syndrome associated with leukaemia
An identical twin who developed leukaemia in the first year of life
A family member who has been diagnosed with a germline mutation associated with cancer susceptibility

No of Genes Tested : 14 APC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS2, SDHB, SDHC, SDHD, SMAD4, STK11, TP53 Disorders associated with this panel: 8

Familial Adenomatous Polyposis / Attenuated Familial
Adenomatous Polyposis (APC)
Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
Hereditary diffuse gastric syndrome (CDH1)
Hereditary Paraganglioma-Pheochromocytoma syndrome (SDHB, SDHC, SDHD)
Juvenile Polyposis Syndrome (SMAD4, BMPR1A)
Li-Fraumeni syndrome (TP53)
Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
Peutz-Jeghers syndrome (STK11)

To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Prostate cancer panel - £ 575

Hereditary Prostate cancer panel tests for numerous germline mutations that could cause prostate cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. No of Genes Tested : 15 ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51D, TP53 Disorders associated with this panel: 6

Ataxia-telangiectasia syndrome (ATM)
Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
Li-Fraumeni syndrome (TP53)
Li-Fraumeni syndrome 2 (CHEK2)
Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
PTEN hamartoma syndrome (PTEN)

The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk and are also analysed by this panel: HOXB13, NBN, PALB2, RAD51D To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Pancreatic Cancer Panel - £ 575

Hereditary Pancreatic Cancer Panel tests for numerous germline mutations that could cause pancreatic cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. No of Genes Tested : 17 APC, ATM, BRCA1, BRCA2, BMPR1A, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), EPCAM, MEN1, MLH1, MSH2, MSH6, PALB2, PMS2, SMAD4, STK11, TP53 Disorders associated with this panel: 10

Ataxia-telangiectasia syndrome (ATM)
Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
Familial Adenomatous Polyposis / Attenuated Familial
Adenomatous Polyposis (APC)
Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
Juvenile polyposis syndrome (SMAD4, BMPR1A)
Li-Fraumeni syndrome (TP53)
Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
Multiple endocrine neoplasia type 1 (MEN1)
Peutz-Jeghers syndrome (STK11)

To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Renal cancer panel - £ 575

Hereditary Renal Cancer Panel tests for numerous germline mutations that could cause renal (kidney) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. No of Genes Tested : 13 BAP1, EPCAM, MSH2, MSH6, PMS2, PTEN, SDHAF2, SDHB, SDHC, SDHD, TP53, VHL Disorders associated with this panel: 7

BAP1 mutation-associated disease (BAP1)
Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHC, SDHD)
Li-Fraumeni syndrome (TP53)
Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
PTEN hamartoma syndrome (PTEN)
Von-Hippel Lindau syndrome (VHL)

To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Skin (Xeroderma-Pigmentosum) cancer panel - £ 575

Hereditary Xeroderma Pigmentosum-related cancer panel tests for numerous germline mutations that could cause skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

Who is this test for?

According to genetic testing guidelines, people who might benefit from genetic testing for Xeroderma Pigmentosum-related skin cancers are those who have:
Family or personal history of a hereditary cancer syndrome associated with skin cancers
A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

No of Genes Tested: 9 DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC Disorders associated with this panel: 1 Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC) To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Familial Melanoma cancer panel - £ 575

Hereditary Familial Melanoma cancer panel tests for numerous germline mutations that could cause familial melanoma skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions. Who is this test for? According to genetic testing guidelines, people who might benefit from genetic testing for hereditary melanoma cancers are those that have:

At least two first-degree family members have had metastatic melanoma
At least one family member has had multiple melanomas Family or personal history of a hereditary cancer syndrome associated with melanoma
A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

No of Genes Tested : 7 BAP1, BRCA2, CDK4, CDKN2A (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), PTEN, RB1, TP53 Disorders associated with this panel: 5

BAP1 mutation-associated disease (BAP1)
Hereditary pancreatic-melanoma syndrome (CDKN2A, CDK4)
Li-Fraumeni syndrome (TP53)
PTEN hamartoma syndrome (PTEN)
Retinoblastoma (RB1)

To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Paraganglioma / Pheochromocytoma cancer panel - £ 575

Hereditary Paraganglioma / Pheochromocytoma cancer panel tests for germline mutations in numerous genes that could cause Paraganglioma or Pheochromocytoma cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions. Who is this test for? According to genetic testing guidelines, people who might benefit from genetic testing for Paraganglioma or Pheochromocytoma cancers are those that have:

Family or personal history of a hereditary cancer syndrome associated with paraganglioma / pheochromocytoma cancers
A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

No of Genes Tested : 6 RET, SDHAF2, SDHB, SDHC, SDHD, VHL Disorders associated with this panel : 3

Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHD, SDHC)
Multiple endocrine neoplasia type 2 (RET)
Von-Hippel Lindau syndrome (VHL)

To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Parathyroid Cancer Panel - £550

Hereditary Parathyroid cancer panel tests for germline mutations in the MEN1 gene that could cause parathyroid cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. Who is this test for? According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those who have: At least two first-degree family members who have had parathyroid tumours A personal or family history of a hereditary cancer syndrome associated with parathyroid cancer A family member that has been diagnosed with a germline mutation associated with cancer susceptibility No of Genes Tested: 1 MEN1 Disorders associated with this panel : 1

Multiple endocrine neoplasia type 1 (MEN1)

To get your Appointment Booked, please CLICK HERE

PreSENTIA Hereditary Thyroid cancer panel - £ 550

Hereditary Thyroid cancer panel tests for germline mutations in the RET gene that could cause medullary thyroid cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions. Who is this test for? According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:

At least one first-degree family member who has had thyroid cancer
A personal or family history of a hereditary cancer syndrome associated with thyroid cancer
A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

No of Genes Tested : 1 RET Disorders associated with this panel : 1

Multiple endocrine neoplasia type 2 (RET)

To get your Appointment Booked, please CLICK HERE PreSENTIA Hereditary Pan-Cancer panel - £ 950 Hereditary Pan-Cancer panel tests for numerous germline mutations in a total of 62 genes that could cause several cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to make better and more informed decisions. Who is this test for? According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those who have:

Several family members on the same side of the family with cancer
Multiple cancers in the same family member
Family members with early cancer onset
Family members with rare cancer types
Family members with an unusual type of cancer (breast cancer in a male)
Personal or family history of a hereditary cancer syndrome
A family member who has been diagnosed with a germline mutation associated with cancer susceptibility
History of previous malignancies

No of Genes Tested: 62 APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), CHEK2, DDB2, DICER1, EPCAM, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GREM1, HOXB13, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, POLH, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCA4, STK11, TP53, VHL, XPA, XPC Disorders that are related to this Panel: 24

Ataxia-telangiectasia syndrome (ATM)
BAP1 mutation-associated disease (BAP1)
Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
DICER 1 syndrome (DICER1)
Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
Fanconi anaemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
Hereditary diffuse gastric syndrome (CDH1)
Hereditary mixed polyposis syndrome (GREM1)
Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHD, SDHAF2, SDHC, SDHB)
Juvenile polyposis syndrome (SMAD4, BMPR1A)
Li-Fraumeni syndrome (TP53)
Li-Fraumeni syndrome 2 (CHEK2)
Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
Multiple endocrine neoplasia type 1 (MEN1)
Multiple endocrine neoplasia type 2 (RET)
MUTYH-associated polyposis syndrome (MUTYH)
Peutz-Jeghers syndrome (STK11)
Polymerase proofreading-associated syndrome (POLD1, POLE)
PTEN hamartoma syndrome (PTEN)
Retinoblastoma (RB1)
Von-Hippel Lindau syndrome (VHL)
Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)

The genes that are not linked with hereditary cancer syndrome but are associated with cancer risk are also analysed by this panel: BARD1, MRE11, RAD50, SMARCA4, HOXB13, NBN, RAD51D To get your Appointment Booked, please CLICK HERE For more information, please visit NIPD Genetics NIPD Genetics is a leading innovative biotechnology company active in the field of developing, engineering, and providing in vitro genetic testing solutions. NIPD Genetics laboratories are accredited by CAP, certified by CLIA and ISO standards and provide SAFE, ACCURATE, and RELIABLE in vitro genetic testing services internationally. https://www.nipd.com/products/oncology/presentia/

HOW ACCURATE IS IT?

TARGETED TECHNOLOGY - By focusing only on the genetic changes tested,
PreSENTIA is accurate and precise.
HIGH READ DEPTH - PreSENTIA analyses the locations of the genetic changes hundreds of times, making the test results more sensitive and reliable.

Are you interested in the PreSENTIA test? Here’s it how it works Our healthcare professionals will collect a buccal swab sample from you

The sample will be sent to NIPD's laboratory
The sample will be analysed at NIPD's laboratory
Results will be sent to you within 2-3 weeks

Hereditary Cancer Syndromes characteristics

If you have cancer in your family history and want to know about your own risk, PreSENTIA can help. By identifying the mutated genes that could cause hereditary cancer syndromes, PreSENTIA can provide information that could help in clinical management. If you have been diagnosed with cancer and have any of the above characteristics, you might also have hereditary cancer syndrome. Identifying this can help reveal how and why your cancer was caused.

PreSENTIA Genetic Cancer Screening Test – FAQ

1. What is cancer?
Cancer occurs when cells grow uncontrollably and abnormally, disrupting normal body functions. It is a leading cause of death worldwide, responsible for 1 in 6 deaths. Early detection, regular monitoring, and proactive medical care are key strategies to reduce mortality.

2. How does cancer develop?
Cancer develops when certain genes that regulate cell growth and repair become altered. These changes can be:

Sporadic: Mutations develop over time due to lifestyle factors, infections (like HPV), or environmental exposure. These are not inherited.
Hereditary: Genetic mutations are inherited from parents and are present from birth. Hereditary mutations account for 5–10% of all cancers.

3. What are germline mutations?
Germline mutations are inherited DNA changes present in all cells from birth. Individuals with germline mutations in cancer-related genes have a higher lifetime risk of developing cancer. When cancer develops due to these mutations, it is classified as hereditary cancer.

4. What is a hereditary cancer screening test?
A hereditary screening test identifies whether an individual carries a gene mutation that increases cancer susceptibility. If a family member has hereditary cancer or a known genetic mutation, other relatives may also carry it. The test helps detect risks early, guide prevention, and inform medical planning.

5. What does cancer susceptibility mean?
Cancer susceptibility (or predisposition) refers to an individual’s likelihood of developing cancer due to inherited genetic changes. Certain mutations can compromise genes that normally protect against disease, increasing the risk of specific cancers.

6. Who should consider the PreSENTIA Genetic Cancer Test?
This test is recommended for:

People with a strong family history of cancer
Individuals with relatives diagnosed at an early age
Families with multiple cancer cases or rare cancer types
Anyone with a personal or family history of hereditary cancer syndromes
Individuals whose relatives have known genetic mutations linked to cancer

7. What are hereditary cancer syndromes?
Hereditary cancer syndromes are inherited conditions that increase the risk of developing specific cancers. Mutations in genes critical for normal cell growth and repair lead to these syndromes, which can be passed from one generation to the next.

8. What is the PreSENTIA Genetic Cancer Screening Test?
The PreSENTIA test is a comprehensive, DNA-based screening designed to detect genetic mutations linked to higher cancer risk. It provides personalised insights to help guide early detection, prevention strategies, and tailored treatment planning.

9. What cancers does PreSENTIA test for?
The test screens for hereditary risk of multiple cancers, including:

Breast cancer
Ovarian cancer
Colorectal cancer
Prostate cancer
Pancreatic cancer
Melanoma
Other hereditary cancers

10. How is the PreSENTIA test performed?
A simple saliva or blood sample is collected by a trained healthcare professional using a painless, non-invasive method. The sample is sent to a certified laboratory for analysis.

11. How long will it take to receive results?
Results are usually available within 2–3 weeks after the lab receives your sample. The report includes a clear interpretation, risk assessment, and recommended follow-up actions.

12. How should I interpret my test results?

Positive: Indicates a genetic mutation that increases cancer risk. A genetic counsellor or healthcare provider will discuss prevention, monitoring, and treatment options.
Negative: No mutation detected in the genes tested, but it does not eliminate all cancer risk. Routine screenings are still advised.

13. Are the results confidential?
Yes. All results are handled securely and delivered through password-protected reports. Genetic counselling sessions are confidential, maintaining strict privacy.

14. Can family members benefit from this test?
Yes. Identifying a genetic mutation in one individual can inform testing and preventive measures for close relatives who may also carry the mutation.

15. What are the advantages of PreSENTIA over other screenings?

Detects hereditary cancer risk before symptoms appear
Enables personalised prevention and monitoring plans
Provides access to expert genetic counselling
Non-invasive and safe with accurate results

16. Is the test safe?
Absolutely. Saliva or blood collection is painless, non-invasive, and poses no risk to the patient.

17. Should I consult a doctor before taking the test?
It is recommended to consult a healthcare provider or genetic counsellor to select the most appropriate gene panels based on personal and family medical history.

18. How do I book the PreSENTIA Genetic Cancer Test at Miracle Inside?
Appointments can be booked by calling 01138301371 or online through our website. A deposit is required to secure the test, with the remaining balance payable after the appointment.

19. When should I consider testing?
Testing is beneficial if you have a family history of cancer, are planning preventive measures, or want early detection strategies for hereditary cancers. Early identification helps implement effective screening and prevention plans.

20. How does PreSENTIA support proactive health planning?
By identifying genetic predisposition, the PreSENTIA test empowers individuals and families to make informed decisions about:

Lifestyle adjustments
Early screening programs
Preventive treatment options
Genetic counselling for family members

To secure your appointment at Miracle Inside Diagnostic Scan Centre, the following payments are required:

Deposit: A non-refundable deposit of £30.
Phlebotomy Charges: An additional fee of £35 is charged for phlebotomy services and the DHL courier service to timely deliver the blood to the laboratory.

These payments must be made when booking to confirm your appointment. The remaining balance for your services can be paid after your appointment at our clinic. This ensures a smooth and efficient process for both our staff and patients.

The Appropriate cancellation charge will apply as shown below.

Amendments: 72 hrs ( 3 days Notice )
Bookings made on the same day or 1 to 3 days before your appointment cannot be amended.
Refund Applicable: 14 Days or more: Full refund
Between 10 and 14 days: £30 non-refundable deposit balance paid will be refunded
Between 1 and 9 days: No refund will be given
Failure to attend: No refund will be given
Rescheduled Appointments are not eligible for Cancellation or Refunds.

Book now to reserve your spot for Hereditary Cancer Screening Leeds ( PreSENTIA ) To get your Appointment Booked, please CLICK HERE

Book an appointment with GODSON JOHNSON using Setmore

Book Now £495